Humanized antibody neutralizing 2009 pandemic H1N1 virus

Biotechnology Journal

Volumn 9, Issue 12, 2014, Pages 1594-1603

  Shembekar, Nachiket ^a   Mallajosyula, Vamsee V Aditya ^b   Chaudhary, Piyush ^a   Upadhyay, Vaibhav ^a   Varadarajan, Raghavan ^b   Gupta, Satish Kumar ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

2009 pandemic H1N1; Antibody humanization; CDR grafting; Epitope mapping; Neutralizing monoclonal antibodies

Indexed keywords

CELL CULTURE; CLOCK AND DATA RECOVERY CIRCUITS (CDR CIRCUITS); DRUG THERAPY; EPITOPES; GRAFTING (CHEMICAL); MAMMALS; MONOCLONAL ANTIBODIES;

2009 PANDEMIC H1N1; COMPLEMENTARITY-DETERMINING REGIONS; EPITOPE MAPPING; HEAVY AND LIGHT CHAINS; HUMANIZED ANTIBODY; MAMMALIAN CELL LINES; MONOCLONAL ANTIBODIES (MABS); NEUTRALIZING ANTIBODIES;

VIRUSES;

HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2077; MONOCLONAL ANTIBODY 2077HU2; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; COMPLEMENTARITY DETERMINING REGION; IMMUNOGLOBULIN G;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL LINE; CHO K1 CELL LINE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DRUG ISOLATION; EPITOPE MAPPING; HEAVY CHAIN; IC50; INFLUENZA VIRUS A H1N1; LIGHT CHAIN; MAMMAL CELL; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; REVERTANT; AMINO ACID SEQUENCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DOG; GENETICS; HUMAN; IMMUNOLOGY; MDCK CELL LINE; METABOLISM; MOLECULAR GENETICS;

INFLUENZA A VIRUS; MAMMALIA; MURINAE; ORTHOMYXOVIRIDAE; SUIDAE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; CHO CELLS; COMPLEMENTARITY DETERMINING REGIONS; CRICETULUS; DOGS; EPITOPE MAPPING; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA;

EID: 84925944399     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400083     Document Type: Article

References (44)

1. Dawood, F. S., Iuliano, A. D., Reed, C., Meltzer, M. et al., Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study. Lancet Infect. Dis. 2012, 12, 70121-70124.
2. Couch, R. B., Kasel, J. A., Immunity to influenza in man. Annu. Rev. Microbiol. 1983, 37, 529-249.
3. Corti, D., Voss, J., Gamblin, . J., Codoni, G. et al., A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 6044, 850-856.
4. Koudstaal, W., Koldijk, M. H., Brakenhoff, J. P., Cornelissen, L. A. et al., Pre- and post exposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: Viable alternative to oseltamivir. J. Infect. Dis. 2009, 12, 1870-1873.
5. Sui, J., Hwang, W. C., Perez, S., Wei, G. et al., Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 3, 265-273.
6. Rinaldi, C., Penhale, W. J., Stumbles, P. A., Tay, G. et al., Modulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis. PLoS ONE 2014, 2, e89674.
7. Sawyer, L. A., Antibodies for the prevention and treatment of viral diseases. Antiviral Res. 2000, 2, 57-77.
8. Sharon, J., Rynkiewicz, M. J., Lu, ., Yang, C. Y., Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. Immunology 2014, 142, 1-23.
9. Shawler, D. L., Bartholomew, R. M., Smith, L. M., Dillman, R. O., Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 1985, 2, 1530-1535.
10. Clark, M., Antibody humanization: A case of the 'Emperor's new clothes′? Immunol. Today 2000, 8, 397-402.
11. Almagro, J. C., Fransson, J., Humanization of antibodies. Front. Biosci. 2008, 13, 1619-1633.
12. Shembekar, N., Mallajosyula, V. V., Mishra, A., Yeolekar, L. et al., Isolation of a high affinity neutralizing monoclonal antibody against 2009 pandemic H1N1 virus that binds at the 'Sa' antigenic site. PLoS ONE 2013, 8, e55516.
13. Reed, L. J., Muench, H. A., Simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27, 493-497.
14. Morrison S. L., Cloning, expression and modification of antibody V regions. Curr. Protoc. Immunol. 2002, Chapter 2: Unit 2.12.
15. Kabat E. A., Wu T. T., Perry H. M., Gottesman K. S. et al., Sequences of Proteins of Immunological Interest, Vol. Publ. No. 91-3242, United States Department Health and Human Services, NIH 1991.
16. Chothia, C., Lesk, A. M., Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 1987, 196, 901-917.
17. Hwang, W. Y., Almagro, J. C., Buss, T. N., Tan, P. et al., Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods 2005, 36, 35-42.
18. Chothia, C., Novotný, J., Bruccoleri, R., Karplus, M., Domain association in immunoglobulin molecules: The packing of variable domains. J. Mol. Biol. 1985, 186, 651-663.
19. Chothia, C., Lesk, A. M., Tramontano, A., Levitt, M. et al., Conformations of immunoglobulin hypervariable regions. Nature 1989, 342, 877-883.
20. Foote, J., Winter, G., Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 1992, 224, 487-499.
21. Whitelegg, N. R., Rees, A. R., WAM: An improved algorithm for modeling antibodies on the WEB. Protein Eng. 2000, 13, 819-824.
22. Kingston R. E., Chen C. A., Okayama H., Calcium phosphate transfection. Curr. Protoc. Immunol. 2001, Chapter 10: Unit 10.13.
23. Gietz, R. D., Schiestl, R. H., High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2007, 2, 31-34.
24. Boder, E. T., Wittrup, K. D., Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol. 2000, 328, 430-444.
25. Chao, G., Cochran, J. R., Wittrup, K. D., Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J. Mol. Biol. 2004, 342, 539-550.
26. Abhinandan, K. R., Martin, A. C., Analyzing the "degree of humanness" of antibody sequences. J. Mol. Biol. 2007, 369, 852-862.
27. Cabral, T. M., Berhane, Y., Schmidt, L., Tracz, D. M. et al., Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009). J. Virol. Methods 2012, 1, 25-33.
28. Manicassamy, B., Medina, R. A., Hai, R., Tsibane, T. et al., Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 2010, 1, e1000745.
29. Chen, J., Yan, B., Chen, Q., Yao, Y. et al., Evaluation of neutralizing efficacy of monoclonal antibodies specific for 2009 pandemic H1N1 influenza A virus in vitro and in vivo. Arch. Virol. 2014, 3, 471-483.
30. Sakabe, S., Iwatsuki-Horimoto, K., Horimoto, T., Nidom, C. A. et al., A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res. 2010, 3, 249-255.
31. Burioni, R., Canducci, F., Mancini, N., Clementi, N. et al., Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiol. 2009, 4, 319-324.
32. Nelson, A. L., Dhimolea, E., Reichert, J. M., Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 2010, 10, 767-774.
33. Chen, Y., Luo, W., Wu, W. L., Fang, Z. et al., Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1. Antiviral Res. 2010, 87, 81-84.
34. Zheng, Q., Xia, L., Wu, W. L., Zheng, Z. et al., Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses. Antimicrob. Agents Chemother. 2011, 55, 1349-1357.
35. Gogolák, P., Réthi, B., Hajas, G., Rajnavölgyi, E., Targeting dendritic cells for priming cellular immune responses. J. Mol. Recognit. 2003, 16, 299-317.
36. Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W. et al., A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 1989, 86, 10029-10033.
37. Riechmann, L., Clark, M., Waldmann, H., Winter, G., Reshaping human antibodies for therapy. Nature 1988, 332, 323-327.
38. Verhoeyen, M., Milstein, C., Winter, G., Reshaping human antibodies: Grafting an antilysozyme activity. Science 1988, 239, 1534-1536.
39. Saldhana J. W., Molecular Engineering I: Humanization. in: Dubel S. (Eds.), Handbook of Therapeutic Antibodies, Wiley-VCH, Weinheim 2007.
40. Dharshanan, S., Chong, H., Hung, C. S., Zamrod, Z., Development of humanized monoclonal antibody by logical approach: Characterization, functional studies in vitro and immunogenicity studies in vivo in nonhuman primates. Sci. Res. Essays 2012, 7, 2288-2299.
41. Makabe, K., Nakanishi, T., Tsumoto, K., Tanaka, Y. et al., Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J. Biol. Chem. 2008, 283, 1156-1166.
42. Singer, I. I., Kawka, D. W., DeMartino, J. A., Daugherty, B. L. et al., Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences. J. Immunol. 1993, 150, 2844-2857.
43. Krause, J. C., Tsibane, T., Tumpey, T. M., Huffman, C. J. et al., A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J. Virol. 2011, 20, 10905-10908.
44. Zhiqiang A., Therapeutic Monoclonal Antibodies: From Bench to Clinic, Wiley, New Jersey 2009.